Just a quick up date. I recieved the letter below Vernon Coaker MP recieved from NHSE 're Ibrutinib. It doesn't address the 3 year issue and I've asked him if he would write back to specifically address that point. A letter is going out today.
You will also notice a slight change in attitude. Hopefully the evidence presented in July will be be enough to reverse the decision. Whether it's in time for I don't know but it will help many.
Stay well Mick
Our ref: PH5940
80 London Road
Vernon Coaker MP
House of Commons
25 June 2018
Dear Mr Coaker,
Re: Ibrutinib for Chronic Lymphocytic Leukaemia
Thank you for your email of 17 May on behalf of a number of your constituents. I am responding as the National Director for Specialised Services.
NHS England funds ibrutinib in line with the National Institute for Health and Care Excellence (NICE) guidance. Therefore, since January 2017, NHS England has routinely commissioned ibrutinib for relapsed / refractory chronic lymphocytic leukaemia and chronic lymphocytic leukaemia with 17p deletion or TP53 mutation. Prior to this, ibrutinib was funded via the Cancer Drugs Fund.
You may be aware that NICE has recently issued a clarification around the scope of its guidance and recommendation for ibrutinib in this indication. Specifically, they have confirmed that ‘it is reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment’ and that because the guidance itself does not define unsuitability for retreatment it is ‘appropriate for NHS England, as the commissioner, to take clinical advice in order to do so’.
This is what we have therefore done. However we are more than willing to receive and review, by the end of July 2018, any further evidence that patients and clinicians wish to submit on this matter.
Acting Director of Specialised Commissioning
High quality care for all, now and for future generations